RxDoctor Payments Data

John Moffa, MD

Internal Medicine · Columbus, OHNPI 1962489179

Payments from drug & device makers

$556in general payments, 2019–2025

Across 29 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • Pfizer$91
  • Viiv Healthcare Company$48
  • Merck$43
  • Gilead$30
  • GSK$25
  • plus $101 from 6 others

What the payments were for

  • Food & beverage$52094%
  • Education$366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$556 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$130,374
Medicare patients
212
Services billed
5,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$98,035
JardianceEmpagliflozin49$64,955
OzempicSemaglutide69$62,468
MounjaroTirzepatide44$49,565
JanuviaSitagliptin Phosphate27$39,500
TrulicityDulaglutide38$38,899
XareltoRivaroxaban23$34,356
ProliaDenosumab14$24,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$23,536
Breo ElliptaFluticasone/Vilanterol34$16,416
MyrbetriqMirabegron20$15,178
Diazepam49$12,606
BelsomraSuvorexant29$12,193
Xtampza ErOxycodone Myristate11$5,535
Celecoxib99$4,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$98,03583 claims
Lilly USA, LLCMounjaro, Trulicity$17$88,46482 claims
Boehringer IngelheimJardiance$16$64,95549 claims
MerckJanuvia, Belsomra$43$51,69356 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$25$43,49885 claims
AbbVieSynthroid$218$4,07184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →